Form Approved OMB No. 0920-1385 Exp. Date: 3/31/26

Case report form: Eumy	ycetoma =======
Patient demographic cl	naracteristics
Unique patient ID:	(site_####)
Site submitting case:	
Location of residence fo	or patient (ZIP Code): OR [] Unknown
Age at diagnosis (years)	:
Assigned sex at birth: []	Male [] Female OR [] Unknown
Gender identity: [] Male	e [] Female [] Transgender, non-binary, or another gender
[] Prefer not to	answer/Decline OR [] Unknown
Race and/or ethnicity (s	select all that apply and enter additional details in the spaces provided):
[] American Ind	ian or Alaska Native
Montar	or example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of na, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Inity, Aztec, Maya, etc.
[] Asian – provid	de details below
	[] Asian Indian [] Filipino [] Vietnamese [] Korean [] Japanese or example, Pakistani, Hmong, Afghan, etc.
[] Black or Africa	an American – provide details below
[] African Am Enter, f	nerican [] Jamaican [] Haitian [] Nigerian [] Ethiopian [] Somali or example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc.
[] Hispanic or La	atino – provide details below
[] Mexican	[] Puerto Rican [] Salvadoran [] Cuban [] Dominican [] Guatemalan

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

[] Middle Eastern or North African – provide details below
[] Lebanese [] Iranian [] Egyptian [] Syrian [] Iraqi [] Israeli
Enter, for example, Moroccan, Yemeni, Kurdish, etc.
[] Native Hawaiian or Pacific Islander – provide details below
[] Native Hawaiian [] Samoan [] Chamorro [] Tongan [] Fijian [] Marshallese
Enter, for example, Chuukese, Palauan, Tahitian, etc.
[] White – provide details below
[] English [] German [] Irish [] Italian [] Polish [] Scottish
Enter, for example, French, Swedish, Norwegian, etc.
Monthly household income (USD)
Occupation at time of presumed infection:
Industry at time of presumed infection:
Underlying medical conditions (active or present in the 2 years before symptom onset)
Diabetes mellitus [] Yes [] No [] Unknown
Chronic kidney disease [] Yes [] No [] Unknown If yes, on dialysis? [] Yes [] No [] Unknown If yes, GFR < 60? [] Yes [] No
Liver cirrhosis? [] Yes [] No [] Unknown Chronic hepatitis without cirrhosis? [] Yes [] No [] Unknown If yes, [] Hep B [] Hep C
Immunocompromising condition [] Yes [] No [] Unknown
[] HIV infection [] HIV infection without AIDS (CD4 ≥ 200)
[] HIV infection with AIDS (CD4 < 200) or chart diagnosis of advanced HIV disease [] Cancer diagnosis, specify

Enter, for example, Colombian, Honduran, Spaniard, etc.

	[] On chemotherapy, specify
r: -	Date of cancer diagnosis (mm/dd/yyyy):
[] Tran	
	[] Solid organ, specify organ [] Hematologic (stem cell)
	Date of transplantation (mm/dd/yyyy):
[] Imm	unosuppressive therapy, specify
[] Othe	er immunocompromised condition, specify
-	nderlying condition not listed (specify):
Exposure histo	ory
-	veled or lived internationally in their life? [] Yes [] No [] Unknown
0	Country 1; Approximate duration of stay (years):
0	Country 2; Approximate duration of stay (years):
0	Country 3; Approximate duration of stay (years):
0	Country 4; Approximate duration of stay (years):
0	Country 5; Approximate duration of stay (years):
Did the patient	t immigrate to the United States? [] Yes [] No [] Unknown
If yes,	date of immigration (mm/dd/yyyy):
If yes,	country immigrated from:
Any traumatic	inoculation ever recalled? [] Yes [] No [] Unknown
If yes,	please describe geographic location (e.g., city, state):
If yes,	please describe the material involved (e.g., thorns, branches):
If yes,	please describe any weather events (e.g., hurricane, flood):
If yes,	please indicate approximate date of traumatic inoculation (mm/dd/yyyy):
Most likely sou	rce of infection, according to clinician
	=======================================
Diagnosis	
	ve health care facility visits (health center, hospital, etc.) for mycetoma symptoms before etoma diagnosis? [] Yes [] No [] Unknown
If yes,	how many visits?
Were there mi	sdiagnoses before being diagnosed with mycetoma [] Yes [] No [] Unknown
What misd	·
•	Please list all misdiagnoses:
Laboratory tes	ting (associated with diagnosis):
[] X-ray [] Not p	performed [] Unknown if performed

date of imaging:; result:		
[] MRI [] Not performed [] Unknown if performed		
date of imaging:; result:		
[] Ultrasound imaging [] Not performed [] Unkn		
date of imaging (mm/dd/yyyy): [] CT Scan [] Not performed [] Unknown if perfo		
date of imaging (mm/dd/yyyy):		
[] Histopathology [] Not performed [] Unknown		
date (mm/dd/yyyy):; typresult:;	oe of stain:	-
[] Cytology [] Not performed [] Unknown if perf	ormed	
date (mm/dd/yyyy):; res		
[] Fungal grain culture [] Not performed [] Unkn	own if performed	
date of collection (mm/dd/yyyy):		gative:
Organism(s):	;	
[] Broad range sequencing [] Not performed [] U	Jnknown if performed	
date of collection (mm/dd/yyyy):	; Type (e.g., 1	8s, ITS):
Positive/Negative: Org.	anism(s)·	
- Oslave, regulive: 015		,
Signs and symptoms noted during patient inte	rview:	
Signs & Symptoms	Yes/No	Onset Date if Known
Localized swelling		
Openings on the skin (sinuses)		
Discharge containing grains		
Macroscopic grain size		
Microscopic grain size Lymph node involvement		
Bone involvement		
Pain		
Itching		
Other symptoms, please describe:		
7 1 71		
Please describe the specific location on the bod for multiple areas affected):	y of the mycetoma lesi	ion(s) (please mark all that apply
[] Head and neck		
[] Trunk		
[] Upper limbs		
[] Buttocks, perineum, genitals		
[] Lower limbs		
Additional comments on anatomical location: _		
Clinical size of mycetoma lesion: Length (cm): _	; Width	n (cm):
Color of grains:		

[] Red							
[] No visible grai	ns						
Did mycetoma c	ause any forr	n of disabi	lity: [] Yes [] N	lo [] Unknowr	า		
If yes, please fill	out the table	below:					
	Disability		Yes/No	Onset Date	Number of da with disabilit		
difficulty in mo	Mild motor impairment (has some difficulty in moving around but is able to walk without help)			Date	With disabilit	y WOIK(I/I	,,
Moderate motor impairment (has some difficulty in moving around, and difficulty in lifting and holding objects, dressing and sitting upright, but is able to walk without help)			ulty				
Severe motor i move around v able to lift or h or sit upright)	vithout help,	and is not					
Treatment Was the patient [] Yes If yes, listeroids) in the te	[] No st all therape		[] Unknown	gals, immune	response modul	lators, antibiotics,	,
Therapeutic Agent Name	Max Daily dose (mg/day)	Route (e.g., IV, PO, IT)	Start Date	Duration of Therapy	Therapy ongoing at time of abstraction	Discontinued due to toxicity. In yes, describe toxicity	Therapeutic f Drug Monitoring (e.g., serum level of antifungal)
			//	days	[] Yes [] No	[] Yes [] No 	[] Yes [] No Level 1: Date: Value:
							Level 2: Date: Value
			//	days	[] Yes [] No	[] Yes [] No 	[] Yes [] No Level 1: Date:

[] Black

[] White/yellow

								Value:
								Level 2:
								Date:
								Value
							[] Yes [] No	[] Yes [] No
			//	days	[] Yes	[] No		11.00 11.00
				,				Level 1:
								Date:
								Value:
								Level 2:
								Date:
							[] \ [] \ []	Value
			, ,	dava	[] \/aa	[] Na	[] Yes [] No	[] Yes [] No
			 //	days	[] Yes	[] No		Lovel 1
								Level 1: Date:
								Value:
								Value.
								Level 2:
								Date:
								Value
							[] Yes [] No	[] Yes [] No
			//	days	[] Yes	[] No		
								Level 1:
								Date:
								Value:
								Level 2:
								Date:
								Value
							[] Yes [] No	[] Yes [] No
			//	days	[] Yes	[] No		
								Level 1:
								Date:
								Value:
								Level 2:
								Date: Value
								value
Notes about treat	ment:							
								
Did the patient un	dergo local :	surgical ex	cision of the e	eumycetoma l	esions: [] Yes []	No [] Unknown	
			mm/dd/yyyy):					
Did the patient red	ceive antimi	crobials be	efore local sur	gical excision	? [] Yes [1 No [] t	Jnknown	

Did the patient receive antimicrobials before local surgical excision? [] Yes [] No [] Unknown

Did the patient undergo regular debridement: [] Yes [] No [] Unknown

Complications:

Outcome	Yes/No	Onset Date	Notes (e.g., location)
Tissue fibrosis			
Ankylosis (abnormal stiffening			
and immobility of a joint due to			
fusion of the bones)			
Massive destruction of a joint			
Pulmonary eumycetoma due to			
secondary spread from a			
subcutaneous lesion			
Bronchopleural cutaneous fistula			
Secondary bacterial infection			
Amputation			
Lymphedema			
Other; specify			

Did the mycetoma infection resolve (clinical and radiographic cure)? [] Yes [] No [] Unknow	Did	the my	ycetoma	infection	resolve	(clinical	and ra	diograp	hic cure)?[]	Yes []	No [Unknov	٧n
---	-----	--------	---------	-----------	---------	-----------	--------	---------	----------	------	--------	------	--------	----

If yes, what was the date of clinical resolution:

If no, what was date of last follow-up (mm/dd/yyyy):

Did this patient die within 2 years after the mycetoma diagnosis? [] Yes [] No [] Unknown

If wo	s, was mycetoma	a contributing	factor in	nationt's doath?	[] Voc	ם או ר	1 Linknown
II VE	S. Was IIIVCELUIIIa	a continuumig	Tactor III	Datient 5 death:	11 165	1 140 1	I OHKHOWH

Additional comments:			

Appendix 2: Dermatology Life Quality Index Tool

Dermatology Life Quality Index Questionnaire:

- 1. Over the last week, how itchy, sore, painful, or stinging has your skin problem been?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
- 2. Over the last week, how embarrassed or self-conscious have you been because of your skin problem?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all

3.	Over the last week, how much has your skin problem interfered with you going shopping or looking
	after your home or garden?
	a. Very much
	b. A lot
	c. A little
	d. Not at all
	e. Not relevant
4.	Over the last week, how much has your skin problem influenced the clothes you wear?
	a. Very much
	b. A lot
	c. A little

5. Over the last week, how much has your skin problem affected any social or leisure activities?

6. Over the last week, how much has your skin problem made it difficult for your to do any sport?

i. If no, over the last week how much has your skin problem been a problem at work

8. Over the last week, how much has your skin problem created problems with your partner or any of

7. Over the last week, has your skin problem prevented you from working or studying

9. Over the last week, how much has your skin problem caused any sexual difficulties?

example by making your home messy, or by taking up time?

10. Over the last week, how much of a problem has the treatment for your skin problem been, for

d. Not at alle. Not relevant

a. Very muchb. A lotc. A littled. Not at alle. Not relevant

a. Very muchb. A lotc. A littled. Not at alle. Not relevant

a. Yesb. No

c. Not relevant

your close friends or relatives?

a. Very muchb. A lotc. A littled. Not at alle. Not relevant

a. Very muchb. A lotc. A littled. Not at alle. Not relevant

or studying?

1. A lot

2. A little

3. Not at all

- a. Very much
- b. A lot
- c. A little
- d. Not at all
- e. Not relevant